New hope for Hard-to-Treat skin cancer: safer chemo combo enters trials

NCT ID NCT07535710

First seen Apr 23, 2026 · Last updated May 07, 2026 · Updated 5 times

Summary

This study tests a new combination of drugs (aclarubicin plus cyclophosphamide, vincristine, and prednisone, called CAOP) in 37 people aged 60+ with relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare skin cancer. The goal is to find the safest dose and see if it shrinks tumors, while avoiding heart damage common with standard chemo. Participants must have advanced disease (stage IIB–IV) and be in good overall health.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEZARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ruijin Hospital Wuxi Branch

    Wuxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.